BMRN vs. KNSA

In the year-to-date period, BMRN achieves a -4.55% return, which is significantly lower than KNSA's 3.94% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for BioMarin Pharmaceutical Inc. (BMRN) and Kiniksa Pharmaceuticals, Ltd. (KNSA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current BMRN Sharpe Ratio is -0.83, which is lower than the KNSA Sharpe Ratio of 0.44. The chart below compares the historical Sharpe Ratios of BMRN and KNSA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither BMRN nor KNSA has paid dividends to shareholders.

The maximum BMRN drawdown since its inception was -90.58%, which is greater than KNSA's maximum drawdown of -83.06%. Use the drawdown chart below to compare losses from any high point for BMRN and KNSA. For additional features, visit the drawdowns tool.

BioMarin Pharmaceutical Inc. (BMRN) has a higher volatility of 17.84% compared to Kiniksa Pharmaceuticals, Ltd. (KNSA) at 15.59%. This indicates that BMRN's price experiences larger fluctuations and is considered to be riskier than KNSA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between BioMarin Pharmaceutical Inc. and Kiniksa Pharmaceuticals, Ltd.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.